Biotechs With Massive Upside [BioCryst Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., AbbVie Inc]
Everybody knows that biotech ideas can become huge gainers for investors, but understanding the technology platforms, the unmet needs and the valuations can be daunting, especially in spaces where a number of players are developing products. In this interview with
The Life Sciences Report, Vernon Bernardino of MLV & Co. brings some clarity and perspective to investors who could reap windfalls from small-cap names in which shareholder value has yet to be created and realized.
The Life Sciences Report: Vernon, up to 30 thousand (30K) people currently have a vital and pressing need for experimental therapeutic and immunization agents to protect them from the ongoing Ebola virus disease (EVD) outbreak in West Africa. That 30K is a conservative estimate, according to University of Oxford epidemiologist Oliver Brady, who wrote an op-ed piece for the World View column of